1-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)ethanone | 1073642-82-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)ethanone
• 英文别名: 1-[3-(2,6-Dimethylphenyl)-5-methoxyphenyl]ethanone
• CAS: 1073642-82-6
• 化学式: C₁₇H₁₈O₂
• 分子量: 254.329
• InChiKey: FLWMEQUQOHCACF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)ethanone 、 甲氧基甲基三苯基氯化膦 在 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 反应 0.83h， 生成 、 1-(2,6-dimethylphenyl)-3-methoxy-5-[(E)-1-methoxyprop-1-en-2-yl]benzene
  参考文献：
  名称：

  Structure-Based Approach to the Development of Potent and Selective Inhibitors of Dihydrofolate Reductase from Cryptosporidium

  摘要：

  Cryptosporidiosis is an emerging infectious disease that can be life-threatening in ail immune-compromised individual and causes gastrointestinal distress lasting up to 2 weeks in an immune-competent individual. There are few therapeutics available for effectively treating this disease. We have been exploring dihydrofolate reductase (DHFR) as a potential target in Cryptosporidium. On the basis of the structure of the DHFR enzyme from C. hominis, we have developed a novel scaffold that led to the discovery of potent (38 nM) and efficient inhibitors of this enzyme. Recently, we have advanced these inhibitors to the next stage of development. Using the Structures of both the protozoal and human enzymes. we have developed inhibitors with nanomolar potency (1.1 nM) against the pathogenic enzyme and high levels (1273-fold) of selectivity over the human enzyme.

  DOI：

  10.1021/jm8009124
• 作为产物：
  描述：

  1-(3-溴-5-甲氧基苯基)乙酮 、 2,6-二甲基苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 以88%的产率得到1-(3-methoxy-5-(2,6-dimethylphenyl)phenyl)ethanone
  参考文献：
  名称：

  Structure-Based Approach to the Development of Potent and Selective Inhibitors of Dihydrofolate Reductase from Cryptosporidium

  摘要：

  Cryptosporidiosis is an emerging infectious disease that can be life-threatening in ail immune-compromised individual and causes gastrointestinal distress lasting up to 2 weeks in an immune-competent individual. There are few therapeutics available for effectively treating this disease. We have been exploring dihydrofolate reductase (DHFR) as a potential target in Cryptosporidium. On the basis of the structure of the DHFR enzyme from C. hominis, we have developed a novel scaffold that led to the discovery of potent (38 nM) and efficient inhibitors of this enzyme. Recently, we have advanced these inhibitors to the next stage of development. Using the Structures of both the protozoal and human enzymes. we have developed inhibitors with nanomolar potency (1.1 nM) against the pathogenic enzyme and high levels (1273-fold) of selectivity over the human enzyme.

  DOI：

  10.1021/jm8009124

文献信息

• HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE
  申请人：University of Connecticut

  公开号：EP2776404B1

  公开（公告）日：2016-07-06
• US8426432B2
  申请人：——

  公开号：US8426432B2

  公开（公告）日：2013-04-23
• US8853228B2
  申请人：——

  公开号：US8853228B2

  公开（公告）日：2014-10-07
• [EN] HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE<br/>[FR] ANALOGUE HÉTÉROCYCLIQUE D'INHIBITEURS DU DIHYDROFOLATE LIÉS À PROPARGYLE RÉDUCTASE
  申请人：UNIV CONNECTICUT

  公开号：WO2013070620A1

  公开（公告）日：2013-05-16

  The compositions and methods described herein disclose the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.
• Structure-Based Approach to the Development of Potent and Selective Inhibitors of Dihydrofolate Reductase from <i>Cryptosporidium</i>
  作者：David B. Bolstad、Erin S. D. Bolstad、Kathleen M. Frey、Dennis L. Wright、Amy C. Anderson

  DOI：10.1021/jm8009124

  日期：2008.11.13

  Cryptosporidiosis is an emerging infectious disease that can be life-threatening in ail immune-compromised individual and causes gastrointestinal distress lasting up to 2 weeks in an immune-competent individual. There are few therapeutics available for effectively treating this disease. We have been exploring dihydrofolate reductase (DHFR) as a potential target in Cryptosporidium. On the basis of the structure of the DHFR enzyme from C. hominis, we have developed a novel scaffold that led to the discovery of potent (38 nM) and efficient inhibitors of this enzyme. Recently, we have advanced these inhibitors to the next stage of development. Using the Structures of both the protozoal and human enzymes. we have developed inhibitors with nanomolar potency (1.1 nM) against the pathogenic enzyme and high levels (1273-fold) of selectivity over the human enzyme.